TY - JOUR
T1 - Unveiling the potential role of micro/nano biomaterials in the treatment of Helicobacter pylori infection
AU - Fathi Kisomi, Misagh
AU - Yadegar, Abbas
AU - Shekari, Tara
AU - Amin, Mohsen
AU - Llopis-Lorente, Antoni
AU - Liu, Chenguang
AU - Haririan, Ismaeil
AU - Aghdaei, Hamid Asadzadeh
AU - Shokrgozar, Mohammad Ali
AU - Zali, Mohammad Reza
AU - Rad-Malekshahi, Mazda
AU - Miri, Amir Hossein
AU - Hamblin, Michael R.
AU - Wacker, Matthias G.
N1 - Publisher Copyright:
© 2024 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2024
Y1 - 2024
N2 - Introduction: Helicobacter pylori causes stubborn infections and leads to a variety of stomach disorders, such as peptic ulcer, chronic atrophic gastritis, and gastric cancer. Although antibiotic-based approaches have been widely used against H. pylori, some challenges such as antibiotic resistance are increasing in severity. Therefore, simpler but more effective strategies are needed. Areas Covered: In this review, basic information on functionalized and non-functionalized micro/nano biomaterials and routes of administration for H. pylori inhibition are provided in an easy-to-understand format. Afterward, in vitro and in vivo studies of some promising bio-platforms including metal-based biomaterials, biopolymers, small-molecule saccharides, and vaccines for H. pylori inhibition are discussed in a holistic manner. Expert Opinion: Functionalized or non-functionalized micro/nano biomaterials loaded with anti-H. pylori agents can show efficient bactericidal activity with no/slight negative influence on the host gastrointestinal microbiota. However, this claim needs to be substantiated with hard data such as assessment of the biopharmaceutical parameters of anti-H. pylori systems and the measurement of diversity/abundance of bacterial genera in the host gastric/gut microbiota before and after H. pylori eradication.
AB - Introduction: Helicobacter pylori causes stubborn infections and leads to a variety of stomach disorders, such as peptic ulcer, chronic atrophic gastritis, and gastric cancer. Although antibiotic-based approaches have been widely used against H. pylori, some challenges such as antibiotic resistance are increasing in severity. Therefore, simpler but more effective strategies are needed. Areas Covered: In this review, basic information on functionalized and non-functionalized micro/nano biomaterials and routes of administration for H. pylori inhibition are provided in an easy-to-understand format. Afterward, in vitro and in vivo studies of some promising bio-platforms including metal-based biomaterials, biopolymers, small-molecule saccharides, and vaccines for H. pylori inhibition are discussed in a holistic manner. Expert Opinion: Functionalized or non-functionalized micro/nano biomaterials loaded with anti-H. pylori agents can show efficient bactericidal activity with no/slight negative influence on the host gastrointestinal microbiota. However, this claim needs to be substantiated with hard data such as assessment of the biopharmaceutical parameters of anti-H. pylori systems and the measurement of diversity/abundance of bacterial genera in the host gastric/gut microbiota before and after H. pylori eradication.
KW - antibiotic resistance
KW - antibiotic therapies
KW - biopharmaceutical principles
KW - H. pylori
KW - H. pylori inhibitory biomaterials
KW - microbiota
UR - http://www.scopus.com/inward/record.url?scp=85202895414&partnerID=8YFLogxK
U2 - 10.1080/14787210.2024.2391910
DO - 10.1080/14787210.2024.2391910
M3 - Review article
AN - SCOPUS:85202895414
SN - 1478-7210
JO - Expert Review of Anti-Infective Therapy
JF - Expert Review of Anti-Infective Therapy
ER -